MSB 3.21% $1.13 mesoblast limited

banter and General Discussion, page-7576

  1. 429 Posts.
    lightbulb Created with Sketch. 61
    Having now read through the contents of the transcript and Q&A transcript twice, it appears quite promising for Mesoblast particularly now that efficacy is not an issue for the FDA. main issue is funding and the timing of funding, can be overcome by partnering up quicker rather than later.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.